Cargando…
Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study
The modified dose (MD) regimen of pembrolizumab (2 mg/kg or 100 mg every 3 weeks) is an alternative option to reduce the financial burden resulting from the extremely high cost of the standard dose (SD) regimen (200 mg every 3 weeks). However, the clinical effectiveness and prognostic outcomes have...
Autores principales: | To, Sheng-Yin, Kao, Li-Ting, Shih, Jui-Hu, Li, I-Hsun, Huang, Tsai-Wang, Tsai, Chen-Liang, Chian, Chih-Feng, Ho, Ching-Liang, Chang, Ping-Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141635/ https://www.ncbi.nlm.nih.gov/pubmed/35627534 http://dx.doi.org/10.3390/ijerph19105999 |
Ejemplares similares
-
Transplant Recipients Using Tacrolimus Had Higher Utilization of Healthcare Services Than Those Receiving Cyclosporine in Taiwan
por: Lin, Yi-Chang, et al.
Publicado: (2019) -
Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer
por: Low, Jia Li, et al.
Publicado: (2021) -
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023) -
Small Clinical Charts
Publicado: (1892) -
Evaluation of dosing strategy for pembrolizumab for oncology indications
por: Freshwater, Tomoko, et al.
Publicado: (2017)